Earlier Treatment Offers New Hope for Children With Duchenne Muscular Dystrophy
Microscopic view of muscle tissue deficient in dystrophin — Courtesy of Binghamton University
A promising study from Binghamton University in New York suggests that children with Duchenne muscular dystrophy may benefit greatly when treatment begins at a very young age—even before clear symptoms appear.
Researchers tested the drug Vamorolone in boys younger than 4 who have Duchenne muscular dystrophy, or DMD. The inherited condition progressively weakens muscles, eventually causing healthy tissue to be replaced by scar tissue.
The children’s early progress brought an especially welcome result.
“We were surprised at the rapid improvement of gross motor skills,” said Professor Eric Hoffman, who helped develop the medication.
Protecting Muscle From the Beginning
DMD occurs when genetic mutations prevent the body from making dystrophin correctly. This protein plays an essential role in keeping muscles healthy and stable.
Because the affected gene is found on the X chromosome, the condition occurs overwhelmingly in boys. Muscle damage begins at birth, but a diagnosis often does not come until noticeable symptoms emerge several years later.
“The destructive processes in muscle start from birth,” Hoffman explained.
That timing presents a major challenge. Once healthy muscle has been replaced by scar tissue, restoring it is extremely difficult. Hoffman and his colleagues therefore explored a hopeful alternative: beginning treatment before extensive damage has taken place.
Standard care has generally introduced anti-inflammatory corticosteroids after symptoms appear. Although these drugs can help, traditional corticosteroids may also slow growth and cause weight gain, mood changes, adrenal suppression, and other complications. Those risks can make families and physicians hesitant to use them in very young children.
An FDA-Approved Treatment With a Better Safety Profile
Hoffman and fellow Binghamton researcher Raju Nagaraju developed Vamorolone, which is marketed under the name Agamree. The Food and Drug Administration approved it for treating DMD in 2023.
Vamorolone was created to deliver the anti-inflammatory benefits associated with corticosteroids while reducing some of their most difficult side effects. Its improved safety profile—particularly regarding childhood growth—gave researchers an opportunity to study whether treatment could begin earlier.
Duchenne muscular dystrophy researchers Eric P. Hoffman and Kanneboyina “Raju” Nagaraju — Credit: Jonathan Cohen for Binghamton University
Young Boys Show Encouraging Motor Improvements
The Phase II open-label study involved 20 boys with DMD. All were at least 2 but younger than 4, and none had previously received steroid treatment.
For 12 weeks, the children received a daily dose of either 2 or 6 milligrams of Vamorolone per kilogram of body weight. Most participants continued taking the medication for about two years through an expanded-access program.
Throughout the research, the team carefully assessed the children’s growth, metabolism, motor abilities, and responses to the drug.
The findings showed improved motor function without an apparent negative effect on growth. The progress among boys receiving the higher dose was particularly notable.
On the Bayley III gross-motor scale, healthy children generally have a normalized score of approximately 10. The participants entered the study with an average score near 5. After only 12 weeks, their average had climbed to about 8.
No serious adverse events occurred during the study. Some children did experience less severe side effects, including weight gain and adrenal suppression, especially among those receiving the higher dose.
The researchers also noted the study’s limitations. It included only a small number of participants and did not have a placebo group, meaning the results will need to be confirmed through larger, randomized clinical trials.
Newborn Screening Could Create Earlier Opportunities
Another encouraging development may help families take advantage of earlier treatment. DMD was recently added to the U.S. Recommended Uniform Screening Panel for newborns, potentially enabling doctors to identify the condition well before muscle weakness becomes visible.
“Hopefully, vamorolone may become an option for these babies if these preliminary data are confirmed,” Hoffman said.
If future research supports these early findings, physicians may be able to move from responding to muscle deterioration toward preventing some of it. By identifying DMD soon after birth and beginning treatment earlier, doctors could have a valuable new opportunity to preserve children’s muscles, mobility, and quality of life.
